Skyrizi (Risankizumab) Denied: Appealing Plaque Psoriasis, PsA, and Crohn's Denials

Skyrizi (risankizumab) is an IL-23 inhibitor FDA-approved for moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderate-to-severe Crohn's disease. It represents a newer generation of biologics that selectively target the IL-23/Th17 pathway and has shown strong clinical response rates across all three indications. But despite its solid evidence base, insurance denials are common — particularly for patients being switched from another biologic, or for those with Crohn's disease where prior TNF therapy requirements are stringently enforced.

Why Skyrizi Gets Denied

Biologic-naive vs. biologic-experienced requirements. For plaque psoriasis, many insurers will cover Skyrizi for patients who have failed conventional systemics (methotrexate, cyclosporine, acitretin) but require prior failure of a TNF inhibitor or another biologic before approving an IL-23 inhibitor. For psoriatic arthritis, step therapy typically requires prior NSAID failure, then DMARD failure, before a biologic is approved. Skyrizi's label does not specify biologic-experienced patients only — but insurer policies often do.

Crohn's step therapy. For Crohn's disease, insurers almost universally require documented failure of at least one TNF inhibitor (adalimumab or infliximab) before approving Skyrizi. The appeal opportunity here is significant: if TNF inhibitors were tried and caused serious adverse events (severe infusion reactions, demyelination, lupus-like syndrome, malignancy, serious infection), those adverse events constitute clinical failure and bypass grounds.

Severity criteria not documented. For plaque psoriasis, "moderate-to-severe" must be clearly established. Insurers want PASI ≥ 12, BSA ≥ 10%, or IGA ≥ 3. For Crohn's, moderate-to-severe disease is typically documented by CDAI score, endoscopic evidence of active inflammation, or elevated fecal calprotectin and CRP. If treating physicians use clinical language without scoring, prior auths get denied.

Formulary position. Some insurers have not yet added Skyrizi to their specialty tier, listing only older IL-23 inhibitors (like Tremfya) or defaulting to IL-17 inhibitors (Cosentyx, Taltz) as preferred agents. This means the denial is formulary-based and requires a non-formulary exception.

Building a Winning Appeal

Establish the indication precisely. Your appeal letter should state: exact FDA indication, disease severity with validated scores, and why Skyrizi specifically is the appropriate choice.

Document prior biologic failures. For each prior biologic or DMARD, list: drug name, start and stop date, dose, and reason for failure (primary non-response, secondary loss of response, adverse event, or safety contraindication). Be specific. "Inadequate response after 16 weeks of full-dose therapy" is far more compelling than "didn't work."

Differentiate Skyrizi's mechanism. For patients who previously failed TNF inhibitors, IL-12/23 inhibitors (Stelara), or IL-17 inhibitors (Cosentyx, Taltz), argue that IL-23-selective inhibition represents a mechanistically distinct approach with demonstrated efficacy in TNF-failure patients. Clinical trials like ADVANCE and MOTIVATE for Crohn's disease specifically enrolled patients who failed TNF therapy.

Request peer-to-peer review. Dermatologists and gastroenterologists are typically well-versed in Skyrizi's trial data. A peer-to-peer call between your specialist and the insurer's reviewer often resolves the denial, particularly when the reviewer is a general practitioner rather than a subspecialist.

Invoke biologic-switching protections. If your insurer is requiring you to re-try a biologic you already tried and failed, cite any applicable state law or plan language preventing required re-trial of previously failed therapies.

For Crohn's Disease Specifically

The SoT trial data for Skyrizi in Crohn's shows sustained remission rates of over 55% at one year in patients who failed prior biologics. This is compelling medical necessity evidence. Include references to AGA and ACG clinical guidelines, both of which recognize Skyrizi as an effective advanced therapy option in moderate-to-severe Crohn's disease.

Also confirm the dosing is correct in your prior authorization request. Skyrizi for Crohn's uses an IV induction dose at weeks 0, 4, and 8 (600 mg IV), then transitions to subcutaneous maintenance (360 mg Q8W). Many prior auth denials occur because the induction dose is flagged as inconsistent with outpatient infusion benefits — clarify the benefit category being billed.

Fight Back With ClaimBack

Whether your Skyrizi denial is for psoriasis, psoriatic arthritis, or Crohn's disease, ClaimBack builds an appeal grounded in your clinical history and the specific language your insurer needs to approve your medication.

Start your Skyrizi appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied